In situ single-cell analysis of canonical breast cancer biomarkers: phenotypic heterogeneity and implications on response to HER2 targeting agents.
G. Serna, E. Garcia, R. Fasani, X. Guardia, T. Pascual, L. Pare, F. Ruiz-Pace, A. Llombart-Cussac, J. Cortes, A. Prat, P. G. Nuciforo
The paper analyzes HER2-positive breast cancer tumors at the single-cell level to identify phenotypic heterogeneity and its implications for response to HER2-targeted therapies.
bioRxiv · Sep 21, 2022 · PreprintPathology